Dynamic adaptive changes of the serum carnitine esters during and after L-carnitine supplementation in patients with maintenance haemodialysis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 71, Issue 4, 2011, Pages 280-286

  Bene, Judit ^a   Csiky, Botond ^a,b   Komlosi, Katalin ^a   Sulyok, Endre ^a   Melegh, Bela ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b FMC Dialysis Center Pecs   (Hungary)

Author keywords

carnitine esters; haemodialysis; L carnitine; mass spectrometry

Indexed keywords

ACYLCARNITINE; CARNITINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; ELECTROSPRAY MASS SPECTROMETRY; END STAGE LIVER DISEASE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; ISOTOPE DILUTION ASSAY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARNITINE; CASE-CONTROL STUDIES; DIETARY SUPPLEMENTS; FEMALE; GLOMERULONEPHRITIS; HUMANS; MIDDLE AGED; NEPHROCALCINOSIS; PROSPECTIVE STUDIES; PYELONEPHRITIS; RENAL DIALYSIS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 79958830269     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2011.560674     Document Type: Article

References (40)

1. Bieber LL. Carnitine. Annu Rev Biochem 1988;57:261-83.
2. Melegh B, Kerner J, Acsadi G, Lakatos J, Sandor A. L-carnitine replacement therapy in chronic valproate treatment. Neuropediatrics 1990;21:40-43. (Pubitemid 20053388)
3. Melegh B, Kerner J, Sandor A, Vinceller M, Kispal G. Effects of oral L-carnitine supplementation in low-birth-weight premature infants maintained on human milk. Biol Neonate 1987;51:185-93. (Pubitemid 17058723)
4. Melegh B, Pap M, Morava E, Molnar D, Dani M, Kurucz J. Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid. J Pediatr 1994;125:317-321. (Pubitemid 24253021)
5. Vaz FM, Melegh B, Bene J, Cuebas D, Gage DA, Bootsma A, Vreken P, van Gennip AH, Bieber LL, Wanders RJ. Analysis of carnitine biosynthesis metabolites in urine by HPLC-electrospray tandem mass spectrometry. Clin Chem 2002;48:826-34. (Pubitemid 34587581)
6. Melegh B, Sumegi B, Sherry AD. Preferential elimination of pivalate with supplemental carnitine via formation of pivaloylcarnitine in man. Xenobiotica 1993;23:1255-61. (Pubitemid 23330754)
7. Komlosi K, Havasi V, Bene J, Sule N, Pajor L, Nicolai R, Benatti P, Calvani M, Melegh B. Histopathologic abnormalities of the lymphoreticular tissues in organic cation transporter 2 deficiency: evidence for impaired B cell maturation. J Pediatr 2007;150:109-11.
8. Stumpf DA, Parker WD, Jr., Angelini C. Carnitine deficiency, organic acidemias, and Reye's syndrome. Neurology 1985;35:1041-5. (Pubitemid 15026279)
9. Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983;63:1420-80.
10. Duran M, Loof NE, Ketting D, Dorland L. Secondary carnitine deficiency. J Clin Chem Clin Biochem 1990;28:359-63. (Pubitemid 20183143)
11. Jakobs BS, Wanders RJ. Fatty acid beta-oxidation in peroxisomes and mitochondria: the first, unequivocal evidence for the involvement of carnitine in shuttling propionyl-CoA from peroxisomes to mitochondria. Biochem Biophys Res Commun 1995;213:1035-41.
12. Evans A. Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis 2003; 41:S13-S26. (Pubitemid 36389776)
13. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003;42:941-67. (Pubitemid 37056103)
14. Pace S, Longo A, Toon S, Rolan P, Evans AM. Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption. Br J Clin Pharmacol 2000;50:441-8.
15. Hedayati SS. Dialysis-related carnitine disorder. Semin Dial 2006;19:323-8.
16. Reuter SE, Faull RJ, Evans AM. L-carnitine supplementation in the dialysis population: are Australian patients missing out? Nephrology (Carlton ) 2008;13:3-16.
17. Rodriguez-Segade S, Alonso dlP, Paz JM, Novoa D, Arcocha V, Romero R, Del RR. Carnitine deficiency in haemodialysed patients. Clin Chim Acta 1986;159:249-56.
18. Wanner C, Forstner-Wanner S, Rossle C, Furst P, Schollmeyer P, Horl WH. Carnitine metabolism in patients with chronic renal failure: effect of L-carnitine supplementation. Kidney Int Suppl 1987;22:S132-S135.
19. Bellinghieri G, Savica V, Mallamace A, Di SC, Consolo F, Spagnoli LG, Villaschi S, Palmieri G, Corsi M, Maccari F. Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr 1983;38:523-31. (Pubitemid 13010197)
20. Debska S, Kawecka A, Wojnarowski K, Prajs J, Malgorzewicz S, Kunicka D, Zdrojewski Z, Walysiak S, Lipinski J, Rutkowski B. Correlation between plasma carnitine, muscle carnitine and glycogen levels in maintenance hemodialysis patients. Int J Artif Organs 2000;23:90-6. (Pubitemid 30192762)
21. Reuter SE, Evans AM, Faull RJ, Chace DH, Fornasini G. Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease. Ann Clin Biochem 2005;42:387-93. (Pubitemid 41354401)
22. Reuter SE, Faull RJ, Ranieri E, Evans AM. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients. Nephrol Dial Transplant 2009;24:990-6.
23. Fouque D, Holt S, Guebre-Egziabher F, Nakamura K, Vianey-Saban C, Hadj-Aissa A, Hoppel CL, Kopple JD. Relationship between serum carnitine, acylcarnitines, and renal function in patients with chronic renal disease. J Ren Nutr 2006;16:125-31.
24. Costa CC, de Almeida IT, Jakobs C, Poll-The BT, Duran M. Dynamic changes of plasma acylcarnitine levels induced by fasting and sunflower oil challenge test in children. Pediatr Res 1999;46:440-4. (Pubitemid 29451830)
25. Bene J, Komlosi K, Magyari L, Talian G, Horvath K, Gasztonyi B, Miheller P, Figler M, Mozsik G, Tulassay Z, Melegh B. Plasma carnitine ester profiles in Crohn's disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes. Br J Nutr 2007;98:345-50. (Pubitemid 47091377)
26. Wanner C, Horl WH. Carnitine abnormalities in patients with renal insufficiency. Pathophysiological and therapeutical aspects. Nephron 1988;50:89-102.
27. Brass EP, Hoppel CL. Carnitine metabolism in the fasting rat. J Biol Chem 1978;253:2688-93. (Pubitemid 8328428)
28. Golper TA, Wolfson M, Ahmad S, Hirschberg R, Kurtin P, Katz LA, Nicora R, Ashbrook D, Kopple JD. Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int 1990;38:904-11.
29. Steiber AL, Weatherspoon LJ, Spry L, Davis AT. Serum carnitine concentrations correlated to clinical outcome parameters in chronic hemodialysis patients. Clin Nutr 2004;23:27-34. (Pubitemid 38219649)
30. R odriguez-Segade S, Alonso dlP, Paz M, Novoa D, Romero R, Arcocha V, Del RR. Carnitine concentrations in dialysed and undialysed patients with chronic renal insufficiency. Ann Clin Biochem 1986;23( Pt 6):671-5.
31. Wanner C, Wackerle B, Boeckle H, Schollmeyer P, Horl WH. Plasma and red blood cell carnitine and carnitine esters during L-carnitine therapy in hemodialysis patients. Am J Clin Nutr 1990;51:407-10.
32. Talian GC, Komlosi K, Decsi T, Koletzko B, Melegh B. Determination of carnitine ester patterns during the second half of pregnancy, at delivery, and in neonatal cord blood by tandem mass spectrometry: complex and dynamic involvement of carnitine in the intermediary metabolism. Pediatr Res 2007;62:88-92. (Pubitemid 46985856)
33. Silva MF, Selhorst J, Overmars H, van Gennip AH, Maya M, Wanders RJ, de Almeida IT, Duran M. Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI-MS/MS. Clin Biochem 2001;34:635-8. (Pubitemid 34159354)
34. Calvani M, Benatti P, Mancinelli A, D'Iddio S, Giordano V, Koverech A, Amato A, Brass EP. Carnitine replacement in end-stage renal disease and hemodialysis. Ann NY Acad Sci 2004;1033:52-66. (Pubitemid 39656738)
35. Marzo A, Arrigoni ME, Mancinelli A, Cardace G, Corbelletta C, Bassani E, Solbiati M. Protein binding of L-carnitine family components. Eur J Drug Metab Pharmacokinet 1991;Spec No. 3:364-8.
36. Ahmad S. L-carnitine in dialysis patients. Semin Dial 2001;14:209-17. (Pubitemid 33720854)
37. Evans AM, Faull R, Fornasini G, Lemanowicz EF, Longo A, Pace S, Nation RL. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Clin Pharmacol Ther 2000;68:238-49.
38. Bennett MJ, Pollitt RJ, Goodman SI, Hale DE, Vamecq J. Atypical riboflavin-responsive glutaric aciduria, and deficient peroxisomal glutaryl-CoA oxidase activity: a new peroxisomal disorder. J Inherit Metab Dis 1991;14:165-73.
39. da Costa Ferreira G. Chronic early postnatal glutaric acid administration causes cognitive deficits in the water maze. Behav Brain Res 2008;187:411-6.
40. Kolker S, Ahlemeyer B, Krieglstein J, Hoffmann GF. 3-Hydroxyglutaric and glutaric acids are neurotoxic through NMDA receptors in vitro. J Inherit Metab Dis 1999;22:259-62. (Pubitemid 29259490)